AR061929A1 - Acidos nucleicos de union al factor derivado de celulas estomales sdf-1 - Google Patents
Acidos nucleicos de union al factor derivado de celulas estomales sdf-1Info
- Publication number
- AR061929A1 AR061929A1 ARP070103212A ARP070103212A AR061929A1 AR 061929 A1 AR061929 A1 AR 061929A1 AR P070103212 A ARP070103212 A AR P070103212A AR P070103212 A ARP070103212 A AR P070103212A AR 061929 A1 AR061929 A1 AR 061929A1
- Authority
- AR
- Argentina
- Prior art keywords
- union
- nucleic acids
- nucleic acid
- factor derived
- sdf
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 6
- 108020004707 nucleic acids Proteins 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title abstract 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06014957 | 2006-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061929A1 true AR061929A1 (es) | 2008-10-01 |
Family
ID=38947372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103212A AR061929A1 (es) | 2006-07-18 | 2007-07-18 | Acidos nucleicos de union al factor derivado de celulas estomales sdf-1 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8314223B2 (enExample) |
| EP (1) | EP2041282B1 (enExample) |
| JP (1) | JP5380287B2 (enExample) |
| KR (2) | KR101561652B1 (enExample) |
| CN (2) | CN101506364B (enExample) |
| AR (1) | AR061929A1 (enExample) |
| AU (1) | AU2007276435C1 (enExample) |
| BR (1) | BRPI0714844B8 (enExample) |
| CA (1) | CA2658267C (enExample) |
| DK (1) | DK2041282T3 (enExample) |
| ES (1) | ES2663404T3 (enExample) |
| MX (1) | MX2009000656A (enExample) |
| PL (1) | PL2041282T3 (enExample) |
| PT (1) | PT2041282T (enExample) |
| RU (1) | RU2590709C2 (enExample) |
| WO (1) | WO2008009437A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5380287B2 (ja) | 2006-07-18 | 2014-01-08 | ノクソン・ファルマ・アクチエンゲゼルシャフト | Ｓｄｆ−１結合核酸 |
| PT2190991T (pt) * | 2007-08-06 | 2019-12-16 | Noxxon Pharma Ag | Ácidos nucleicos que se ligam a sdf 1 e a sua utilização |
| JP5463621B2 (ja) * | 2008-02-27 | 2014-04-09 | ソニー株式会社 | 標的物質の定量方法 |
| WO2009149921A2 (en) * | 2008-06-11 | 2009-12-17 | Bionucleon S.R.L. | Inhibition of hrp-3 using modified oligonucleotides |
| TWI578992B (zh) * | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
| WO2012025251A1 (en) * | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
| SG188220A1 (en) * | 2010-09-09 | 2013-04-30 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
| WO2012055573A1 (en) * | 2010-10-29 | 2012-05-03 | Noxxon Pharma Ag | Use of hepcidin binding nucleic acids for depletion of hepcidin from the body |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| EP3233112A2 (en) * | 2014-12-17 | 2017-10-25 | Cancer Research Technology Limited | Anti-cxcl12 antibody molecules and their uses |
| WO2017178119A1 (en) * | 2016-04-15 | 2017-10-19 | Noxxon Pharma Ag | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| US11221270B2 (en) * | 2018-02-27 | 2022-01-11 | Kevan M Evans | Method and apparatus for detecting slow leaks |
| WO2021178923A1 (en) | 2020-03-06 | 2021-09-10 | Drinksavvy, Inc. | Devices and methods for detecting a target analyte of interest |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT |
| WO2023154452A1 (en) | 2022-02-11 | 2023-08-17 | Waypoint Bio, Inc. | Cellular staining probes for analyte detection |
| TW202430127A (zh) * | 2023-01-19 | 2024-08-01 | 國立陽明交通大學 | 可用於遞送內質網壓力誘導劑或免疫療法的複合奈米粒及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| IE920562A1 (en) * | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| DE69932510T2 (de) * | 1998-03-24 | 2007-02-15 | Chugai Seiyaku K.K. | Vaskularisierungsinhibitoren |
| US6670149B1 (en) * | 1999-03-01 | 2003-12-30 | Millennium Pharmaceuticals, Inc. | TWIK-5 potassium channel nucleic acids and uses therefor |
| US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| EP1133988A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| ATE347695T1 (de) * | 2001-06-07 | 2006-12-15 | Chemocentryx Inc | Zellwanderungsassay |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| GB0225833D0 (en) | 2002-11-06 | 2002-12-11 | Univ Leeds | Nucleic acid ligands and uses therefor |
| WO2006032143A1 (en) | 2004-09-23 | 2006-03-30 | Arc Pharmaceuticals, Inc. | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| WO2006058705A1 (de) * | 2004-11-29 | 2006-06-08 | Noxxon Pharma Ag | Vasopressin bindende l-nukleinsäure |
| ES2385924T3 (es) | 2006-02-02 | 2012-08-03 | Allergan, Inc. | Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares |
| JP5380287B2 (ja) | 2006-07-18 | 2014-01-08 | ノクソン・ファルマ・アクチエンゲゼルシャフト | Ｓｄｆ−１結合核酸 |
| SI2066351T1 (sl) | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba |
| EP2100140B1 (en) | 2006-11-30 | 2015-05-06 | University Of Virginia Patent Foundation | Methods for diagnosing fibrotic lung diseases |
| PT2190991T (pt) | 2007-08-06 | 2019-12-16 | Noxxon Pharma Ag | Ácidos nucleicos que se ligam a sdf 1 e a sua utilização |
| US20090274687A1 (en) | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
-
2007
- 2007-07-18 JP JP2009519869A patent/JP5380287B2/ja not_active Expired - Fee Related
- 2007-07-18 AR ARP070103212A patent/AR061929A1/es active IP Right Grant
- 2007-07-18 MX MX2009000656A patent/MX2009000656A/es active IP Right Grant
- 2007-07-18 WO PCT/EP2007/006387 patent/WO2008009437A2/en not_active Ceased
- 2007-07-18 KR KR1020137020754A patent/KR101561652B1/ko not_active Expired - Fee Related
- 2007-07-18 PT PT77861607T patent/PT2041282T/pt unknown
- 2007-07-18 BR BRPI0714844A patent/BRPI0714844B8/pt active IP Right Grant
- 2007-07-18 KR KR1020097000923A patent/KR101466931B1/ko active Active
- 2007-07-18 PL PL07786160T patent/PL2041282T3/pl unknown
- 2007-07-18 CN CN2007800305243A patent/CN101506364B/zh active Active
- 2007-07-18 EP EP07786160.7A patent/EP2041282B1/en active Active
- 2007-07-18 DK DK07786160.7T patent/DK2041282T3/en active
- 2007-07-18 AU AU2007276435A patent/AU2007276435C1/en active Active
- 2007-07-18 RU RU2009105494/10A patent/RU2590709C2/ru active
- 2007-07-18 CA CA2658267A patent/CA2658267C/en active Active
- 2007-07-18 CN CN201310486348.1A patent/CN103555725B/zh active Active
- 2007-07-18 ES ES07786160.7T patent/ES2663404T3/es active Active
-
2009
- 2009-01-18 US US12/374,311 patent/US8314223B2/en active Active
-
2012
- 2012-10-13 US US13/651,385 patent/US9035038B2/en active Active
-
2015
- 2015-05-06 US US14/705,809 patent/US9822369B2/en active Active
-
2017
- 2017-11-20 US US15/818,618 patent/US20180163207A1/en not_active Abandoned
-
2020
- 2020-11-09 US US17/092,390 patent/US20210139909A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2544967T3 (es) | Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas | |
| BRPI0707612B8 (pt) | vaso lacrado e formulações líquidas contidas no mesmo | |
| CL2018000537A1 (es) | Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009). | |
| BR112012015740A2 (pt) | anticorpos de anti-flt3 e metodos de uso dos mesmos | |
| CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
| BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
| MX2010002753A (es) | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas. | |
| CY1110860T1 (el) | Αναστροφη μεταγραφαση τελομερασης πτηνου | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| AR066395A1 (es) | Reovirus que tienen secuencias modificadas | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
| BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
| BR112022008192A2 (pt) | Queratina bd-4, sua preparação e composições farmacêuticas e uso | |
| BRPI0714844B8 (pt) | molécula de ácido nucleico e seus usos, composição farmaceutica e complexo | |
| FR2869803B1 (fr) | Particules activables, preparation et utilisations | |
| AR071334A1 (es) | Gel de quitosano para aplicaciones dermatologicas, proceso de obtencion y uso del mismo | |
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| CL2011001128A1 (es) | Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas. | |
| BRPI0911681B8 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro | |
| BR112012020173A2 (pt) | anticorpos. | |
| MX2010002018A (es) | Peptido de cdh3 y agente medicinal que comprende al mismo. | |
| CO6351803A2 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |